


REMARKS

Claims 1-17 and 40-42 are currently pending in the present application. Applicants have amended the claims to place them in form appropriate to US practice, and to reduce the filing fee by, *inter alia*, removing multiple dependency. Applicants have amended the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter
Attorney for Applicant
Registration No. 45,889

Date:
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1467
Facsimile: 919-483-7988